Amarin Corp Plc (AMRN)

[Cardiologymd]

As a medical doctor i am 100 percent sure the label will be expanded for Vascepa. Any other outcome is equal to killing patients. FDA has no choice but to expand the label for a drug that improves CV mortality and no side effects. Not sure why everyone is making a big deal out of label expansion approval.

Some other issues i have seen on this board that need clarifications.

I see people mentioning Repatha as a competitor to Vascepa. That is absolutely not true. Repatha and Vascepa are not competing against each other. Repatha is added when patient cannot achieve lower LDL with statins. Repatha competes with Zetia. Vascepa has no competition.

Another misconception is atrial fibrillation.
If someone already has AFIB who cares about increased risk since they already have AFIB.

Atrial fibrillation by itself is not a dangerous condition and many of us will get it at some point as we age. The only danger of AFIB is a stroke.
However taking Vascepa lowers stroke risk by 28 percent.